Gosset Ownership
Private
Employees
~75
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
35Pharma General Information
35Pharma has initiated Phase 1 clinical trials for its two lead assets. HS235 is being evaluated in overweight and obese healthy subjects, while HS135 is advancing toward proof-of-concept studies in pulmonary hypertension and heart failure with preserved ejection fraction. Both assets are designed to selectively inhibit pathological Activin and GDF signaling implicated in cardiometabolic and pulmonary diseases. No efficacy data from these trials have been published yet.
Contact Information
Drug Pipeline
HS135
Phase 1Key Partnerships
No specific major pharma partnerships disclosed publicly as of May 2025; company notes experience with pharma partnerships among leadership but no named deals.
35Pharma Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Nov 27, 2024 | $53.0M | Completed | Phase 1 |
To view 35Pharma's complete valuation and funding history, request access »